Cereno Scientific publishes addendum to prospectus

Cereno Scientific AB (”Cereno Scientific” or “the Company”) has prepared an addendum to the prospectus regarding "Invitation to subscribe for shares in Cereno Scientific AB (publ)", approved by the Swedish Financial Supervisory Authority on 20 maj, 2019 and published on the same day ("Prospectus"). The Addendum Prospectus is a part of, and should be read together with, the Prospectus.

The Addendum Prospectus has been prepared following three announcements made by the Company. On May 22, 2019, the Company announced its submission of application for the start of clinical Phase II-study to the Russian authorities. On May 23, 2019, the Company announced appointment of Mangold as liquidity provider. On May 31, 2019, the Company announced its submission of application for the start of clinical Phase II-study to the Bulgarian authorities.

The Addendum Prospectus has been approved by the Swedish Financial Supervisory Authority on and will be available on Cereno Scientific's website (www.cerenoscientific.se) and Mangold's website (www.mangold.se) and will be made available on the Swedish Financial Supervisory Authority´s website (www.fi.se).

Investors who prior to publication of this Addendum Prospectus have made a notification or otherwise agreed to purchase or subscribe for the securities covered by the Prospectus pursuant to Chapter 2, Section 34 of the Financial Instruments Trading Act (1991: 980), entitled to withdraw its notification or consent until December 18, 2018 (ie within two business days from the publication of the Addendum Prospectus). Withdrawal must be made in writing to Mangold Fondkommission AB, subject: Cereno Scientific, Box 556 91, 102 15 Stockholm, Sweden or by e-mail to ta@mangold.se. The date of recall taken into account is the date the post was stamped, or when the e-mail was sent to Mangold. Investors who have subscribed shares through trustees should contact their trustees regarding revocation. Unsubscribed subscriptions will remain binding and if investors wish to remain as subscribers of shares, they do not need to take any action.

For further information, please contact:
Daniel Brodén  – CFO
Tel: +46 768 66 77 87
E-mail: info@cerenoscientific.com

About Cereno Scientific AB 
Cereno Scientific is developing novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. In parallel with the development of CS1, Cereno Scientific develops CS014, a preclinical phase compound with promising and innovative characteristics in cardiovascular diseases. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.

Important information

This press release is not an offer to subscribe for shares in Cereno Scientific and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Cereno Scientific will only be made through the prospectus.

This press release shall not, directly or indirectly, be released, published or distributed in or to the ed States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions.

Neither subscription rights, shares subscribed for ("BTA"), newly issued shares or warrants have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA, newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further prospectus is established, registered or that any other measure is undertaken beyond that required by Swedish law.

There is no intention to register any portion of the offer in the United States and the securities issued in the Rights Issue will not be offered to the public in the United States.

This press release may contain certain forward-looking information that reflects Cereno Scientific’s current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. Cereno Scientific makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.


Documents & Links